Cdymax receives FDA warning letter on drug testing practices

Indian API maker Cdymax hit with FDA warning letter tied to drug ingredients testing. The company received a regulatory notice from the US FDA regarding deficiencies in its drug ingredient testing procedures. This warning letter signals compliance concerns at the manufacturing facility and may impact its ability to supply APIs to global pharma clients. Investors should monitor for remedial action updates and potential client impacts.

📊 SECTOR: Pharma | #MEDIUMIMPACT #Regulatory